在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human heparin-binding epidermal growth factor-like growth factor,HB-EGF ELISA Kit

  • 中文名稱:
    人肝素結(jié)合EGF樣生長因子(HBEGF)酶聯(lián)免疫試劑盒
  • 貨號:
    CSB-E09716h
  • 規(guī)格:
    96T/48T
  • 價格:
    ¥3200/¥2500
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    人肝素結(jié)合EGF樣生長因子(HBEGF)酶聯(lián)免疫試劑盒(CSB-E09716h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的HBEGF含量。HBEGF(肝素結(jié)合表皮生長因子樣生長因子)是表皮生長因子家族成員,在細胞生長、遷移、分化等多種生理過程中發(fā)揮重要作用。其研究機制涉及與特定受體結(jié)合激活下游信號通路,參與腫瘤發(fā)生發(fā)展,在心血管疾病、組織修復(fù)等領(lǐng)域也有研究。試劑盒檢測范圍為62.5 pg/mL-4000 pg/mL,探究HBEGF在炎癥反應(yīng)、腫瘤侵襲性研究或再生醫(yī)學(xué)模型中的動態(tài)表達;心血管疾病機制研究、腫瘤微環(huán)境分析及干細胞分化調(diào)控等基礎(chǔ)科研本品僅用于科研,不用于臨床診斷,產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名:
    diphtheria toxin receptor (heparin-binding EGF-like growth factor) ELISA Kit; diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) ELISA Kit; Diphtheria toxin receptor ELISA Kit; DT R ELISA Kit; DT-R ELISA Kit; DTR ELISA Kit; DTS ELISA Kit; DTSF ELISA Kit; HB-EGF ELISA Kit; HBEGF ELISA Kit; HBEGF_HUMAN ELISA Kit; HEGFL ELISA Kit; Heparin binding EGF like growth factor ELISA Kit; Heparin binding epidermal growth factor ELISA Kit; Heparin binding epidermal growth factor like growth factor ELISA Kit; Heparin-binding EGF-like growth factor ELISA Kit; Proheparin binding EGF like growth factor ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    62.5 pg/mL-4000 pg/mL
  • 靈敏度:
    15.6 pg/mL
  • 反應(yīng)時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領(lǐng)域:
    Signal Transduction
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 線性度:
    To assess the linearity of the assay, samples were spiked with high concentrations of human HB-EGF in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
      Sample Serum(n=4)    
    1:1 Average % 89    
    Range % 84-93    
    1:2 Average % 86    
    Range % 82-91    
    1:4 Average % 92    
    Range % 85-96    
    1:8 Average % 105    
    Range % 98-109    
  • 回收率:
    The recovery of human HB-EGF spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 88 83-92    
    EDTA plasma (n=4) 97 92-101    
                   
                   
  • 標準曲線:
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    pg/ml OD1 OD2 Average Corrected    
    4000 2.214 2.267 2.241 2.141    
    2000 1.291 1.391 1.341 1.241    
    1000 0.699 0.745 0.722 0.622    
    500 0.418 0.412 0.415 0.315    
    250 0.277 0.284 0.281 0.181    
    125 0.169 0.175 0.172 0.072    
    62.5 0.135 0.136 0.136 0.036    
    0 0.099 0.100 0.100      
  • 數(shù)據(jù)處理:
  • 貨期:
    3-5 working days

引用文獻

產(chǎn)品評價

靶點詳情

  • 功能:
    Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. Required for normal cardiac valve formation and normal heart function. Promotes smooth muscle cell proliferation. May be involved in macrophage-mediated cellular proliferation. It is mitogenic for fibroblasts, but not endothelial cells. It is able to bind EGF receptor/EGFR with higher affinity than EGF itself and is a far more potent mitogen for smooth muscle cells than EGF. Also acts as a diphtheria toxin receptor.
  • 基因功能參考文獻:
    1. levels of the angiogenesis mediators endoglin, HB-EGF, BMP-9 and FGF-2 in patients with severe sepsis and septic shock; endoglin and HB-EGF could be involved in the host response of sepsis; additional studies are warrant to investigate their role as biomarker or therapeutic targets in sepsis PMID: 28746898
    2. HB-EGF plays a pro-inflammatory role in the active skin and lung lesions of systemic sclerosis. PMID: 29044628
    3. HB-EGF expression in serum may be a potential therapeutic indicator for novel HB-EGF-targeted therapy in recurrent ovarian cancer. PMID: 29970572
    4. both HBEGF upregulation and apoptosis were rescued by exogenous MMP2 PMID: 28731464
    5. Results support the idea that excess heparin binding epidermal growth factor-like growth factor (HB-EGF) leads to a significant elevation of vascular endothelial growth factor (VEGF) and ventricular dilatation. These data suggest a potential pathophysiological mechanism that elevated HB-EGF can elicit VEGF induction and hydrocephalus. PMID: 27243144
    6. These results suggest that HBEGF is an important EGFR ligand in cervical cancer and that cervical cancer cells are the predominant source of HBEGF. Therefore, we propose an autocrine EGFR stimulation model in cervical carcinomas. PMID: 28498437
    7. macrophage-secreted MMP-9 released HB-EGF from macrophages, which increased MMP9 in OVCA433, resulting in a positive feedback loop to drive HB-EGF release and increase proliferation in co-culture. PMID: 27888810
    8. Genome-wide significant (GWS) associations in single-nucleotide polymorphism (SNP)-based tests (P < 5 x 10(-8)) were identified for SNPs in PFDN1/HBEGF, USP6NL/ECHDC3, and BZRAP1-AS1. PMID: 28183528
    9. HB-EGF is implicated in DNA double strand breaks repair as silencing of HB-EGF increased gammaH2AX foci half-life as well as USP9X expression, two features that could be linked to the observed effect on Mcl-1. PMID: 28970067
    10. Heparan sulfate proteoglycans and heparin derivatives further enhance HBEGF-induced differentiation by forming a complex with the epidermal growth factor receptor PMID: 28174207
    11. this study suggests that HBEGF promotes the formation of gliomas, is necessary for tumor maintenance and therefore may be a novel therapeutic target. PMID: 28368403
    12. Results show that HBEGF is highly expressed in primary ovarian tumors and increases as the disease progresses. PMID: 28668900
    13. Serous carcinomatous component championed by expression of HB-EGF predisposes to recurrence/metastasis in stage I metastasis and recurrence in stage I uterine malignant mixed mullerian tumor. PMID: 26980026
    14. Annexin A2 and HB-EGF are overexpressed and are being secreted into serum in Her-2 negative breast cancer patients. PMID: 27496793
    15. Study demonstrates that HBEGF is post-transcriptionally regulated by low O2 (placental environment) through a mechanism involving interactions of miRNAs with its 3'UTR. PMID: 27701455
    16. MMP14 plays an important mechanistic role in NSCLC progression, by supporting cancer invasiveness, promoting collagen degradation, and releasing HB-EGF, which accelerates lung tumor progression. PMID: 28013056
    17. These results indicate that this new anti-HB-EGF mAb 2-108 would be useful in the diagnosis of HB-EGF-related cancers and would be a strong tool in both basic and clinical research on HB-EGF. PMID: 26974561
    18. This antibody reacts with human HB-EGF but not mouse HB-EGF. No cross-reactivity to other EGFR ligands was observed by antigen ELISA. PMID: 27097072
    19. HB-EGF is a molecular target for the resistance of ovarian cancer to paclitaxel and CRM197 as a HB-EGF-targeted agent might be a chemosensitizing agent for paclitaxel-resistant ovarian carcinoma PMID: 26572150
    20. Data suggest that placental expression of HBEGF, EGF (epidermal GF), and TGFA (transforming GF alpha) is down-regulated in pre-eclampsia as compared to normal term birth; each growth factor blocks cell death/apoptosis of cytotrophoblast cell line. PMID: 25589361
    21. Serum sHB-EGF is closely correlated with advanced stage gastric cancer and can be a promising serological biomarker for GC. PMID: 25717241
    22. Studies indicate that heparin-binding EGF-like growth factor (HB-EGF) is a therapeutic target in some types of cancers. PMID: 25517307
    23. the relative expression of hyalurosome (CD44, HAS3, HB-EGF) genes was found to be reduced in patients prior to topical treatment and to be notably increased following treatment. PMID: 25138066
    24. Urinary levels of NGF and HB-EGF may be potential biomarkers for evaluating outcome of overactive bladder syndrome treatment. PMID: 25510766
    25. HB-EGF is a biomarker for LPA1 receptor activation in human breast and prostate cancers. PMID: 24828490
    26. MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. PMID: 25201063
    27. Suggest high levels of HB-EGF contribute to carotid plaque stabilization and reduce the incidence of acute coronary events. PMID: 25359857
    28. Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. PMID: 24013225
    29. studies suggest disintegrin and metalloproteinase domain-containing protein 12(ADAM 12S) and heparin-binding epidermal growth factor-like growth factor(HB-EGF) are involved in cellular plasticity resulting in production of brown adipose tissue-like cells PMID: 24116709
    30. Knockdown of HSP27 by shRNA decreased HB-EGF plus CXCL5-mediated tumor spheroid formation in a three-dimensional culture system, suggesting that AKT/HSP27 was required for HB-EGF/CXCL5-mediated cancer progression PMID: 24346967
    31. Heparin-binding epidermal growth factor and CD9 are likely implicated in processes that are highly relevant for MS lesion formation PMID: 24038577
    32. HB-EGF acts as a potent paracrine and/or autocrine chemotactic factor as well as a mitogen that mediates HER1 and/or HER4 in the invasion and metastasis of thyroid carcinoma cells. PMID: 23917679
    33. Results suggest that HB-EGF plays a pivotal role in the acquisition of tumor aggressiveness in TNBC by orchestrating a molecular hierarchy regulating tumor angiogenesis. PMID: 23443317
    34. HB-EGF overexpression and Kras(G12D) together, but neither alone, increase cancer cell proliferation. PMID: 23376846
    35. Correlation has been found between HB-EGF expression/immunostaining and the different types of analyzed soft tissue sarcomas. PMID: 23597914
    36. The study suggest that one of the causes of unexplained miscarriages may result from the impaired expression of heparanase and heparin-binding EGF-like growth factor. PMID: 23907942
    37. A reciprocal cross-talk between intrahepatic cholangiocarcinoma cells and myofibroblasts through the HB-EGF/EGFR axis contributes to CCA progression. PMID: 23787814
    38. a mechanism of a probiotic-derived soluble protein in modulating intestinal epithelial cell homeostasis through ADAM17-mediated HB-EGF release, leading to transactivation of EGFR. PMID: 24043629
    39. visualized spatiotemporal regulation of proHB-EGF shedding in individual cells using a simple method that measures changes in fluorescence ratios PMID: 23598347
    40. results indicate that Abl kinases negatively regulate HNSCC invasive processes through suppression of an HB-EGF autocrine loop responsible for activating a EGFR-Src-cortactin cascade PMID: 23146907
    41. Our results show that HB-EGF acts as a cell proliferation and cell survival factor in cancer cells. PMID: 23349913
    42. Hypoxia increased the levels and activity of the ADAM12 metalloprotease in a Notch signaling-dependent manner, leading to increased ectodomain shedding of the epidermal growth factor (EGF) receptor (EGFR) ligand heparin-binding EGF-like growth factor. PMID: 23589494
    43. HB-EGF-C nuclear translocation might be crucial in gastric cancer invasion. HB-EGF-C nuclear translocation may offer a prognostic marker and a new molecular target for gastric cancer therapy. PMID: 22646534
    44. expression of HB-EGF in human KCs triggers a migratory and invasive phenotype with many features of epithelial-mesenchymal transition (EMT), which may be beneficial in the context of cutaneous wound healing. PMID: 22592159
    45. Results suggest that heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a target for oral cancer and that CRM197 is effective in oral cancer therapy. PMID: 22718294
    46. variant 1936T prevents hsa-miR-1207-5p from down-regulating HBEGF in podocytes PMID: 22319602
    47. study is the first report demonstrating a role for the ADAM-HBEGF-EGF receptor axis in Ox-PAPC induction of IL-8 in HAECs. PMID: 22402363
    48. These results confirm that polymorphisms in the HGEGF gene are associated with pre-eclampsia. PMID: 22136955
    49. Heparin-binding epidermal growth factor-like growth factor is a potent autocrine regulator of invasion activity in oral squamous cell carcinoma. PMID: 22209887
    50. Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. PMID: 22291012

    顯示更多

    收起更多

  • 亞細胞定位:
    [Heparin-binding EGF-like growth factor]: Secreted, extracellular space. Note=Mature HB-EGF is released into the extracellular space and probably binds to a receptor.; [Proheparin-binding EGF-like growth factor]: Cell membrane; Single-pass type I membrane protein.
  • 數(shù)據(jù)庫鏈接:

    HGNC: 3059

    OMIM: 126150

    KEGG: hsa:1839

    STRING: 9606.ENSP00000230990

    UniGene: Hs.592942



主站蜘蛛池模板: 精品欧美一区二区三区久久久| 亚洲精品av网站在线观看 | 亚洲人成电影在线播放| 国产熟妇疯狂4p交在线播放| 国产av国片精品一区二区| 国产鲁鲁视频在线观看| 国产乱人伦app精品久久 | 2020无码专区人妻系列日韩| 色婷婷久久久swag精品| 天天澡天天揉揉av无码| 公与淑婷厨房猛烈进出视频免费| 久久久国产精品| 午夜精品久久久久久久无码| 久久久欧美国产精品人妻噜噜| 无码不卡中文字幕av| 亚洲中字慕日产2020| 免费看成人aa片无码视频吃奶| 欧美猛少妇色xxxxx猛叫| 国产一区二区三区四区精华| 99精品免视看| 亚洲色偷拍另类无码专区| 婷婷久久综合九色综合绿巨人| 18勿入网站免费永久| 亚洲综合色区中文字幕| 国产乱子伦精品视频| 内射巨臀欧美在线视频| 新版天堂8中文在线最新版官网| 成人精品一区二区三区在线观看| 午夜精品一区二区三区免费视频| 国产爆乳无码视频在线观看3| 亚洲 欧美 另类 综合 日韩| 久久婷婷五月综合国产尤物app| 成人国产片女人爽到高潮| av无码小缝喷白浆在线观看| 国产精品久久久久9999不卡| 日韩精品射精管理在线观看| 人妻内射一区二区在线视频 | 午夜男女爽爽影院免费视频| 国产日产欧产精品品不卡| 欧美人与动牲交a欧美精品| 亚洲aⅴ综合色区无码一区|